The European Medicines Agency (EMA) has approved Ryzneuta (efbemalenograstim alfa) as a treatment to reduce the duration of neutropenia and the incidence of febrile neutropenia in adults treated with ...

Patients considering maintenance lurbinectedin with atezolizumab need comprehensive information about potential adverse effects to make informed treatment decisions with their hea ...

Ziftomenib showed significant efficacy in relapsed/refractory NPM1-mutant AML, achieving deep, durable responses in the KOMET-001 trial. The trial enrolled 92 patients, with 23% achieving complete ...

We conducted an observational study at Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro, Brazil. This is a tertiary care hospital with ~400 beds, including a ...